Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Collaboration Designed to Accelerate Development of Personalized Cancer Therapeutics

By LabMedica International staff writers
Posted on 27 Mar 2016
Two European biotechnology companies are to collaborate on the development of cell and gene based treatment strategies in order to optimize the manufacture and delivery of personalized cancer therapeutics. More...


GlaxoSmithKline (Brentford, United Kingdom) and Miltenyi Biotec (Bergisch Gladbach, Germany) recently announced an agreement to collaborate in a program to merge GlaxoSmithKline’s expertise in developing cell and gene therapy based treatments with Miltenyi Biotec’s cell processing and counting technologies.

Through the collaboration, Miltenyi Biotec will introduce greater automation and high-tech processing technology into GlaxoSmithKline’s current cell and gene therapy research and developing manufacturing capabilities. The goal is to use this increased automation to industrialize cell and gene therapies, overcoming the manufacturing constraints associated with current processes. This should reduce costs and hasten development efforts.

The collaboration will also unite the methodology and expertise of both companies to advance the discovery of new CAR (chimeric antigen-receptor) T-cell based therapeutics, in which cells are engineered to target and destroy cancer cells by strengthening a patient’s natural T-cell response.

Patrick Vallance, president of pharmaceuticals research and development at GlaxoSmithKline, said, “Cell based gene therapies are living treatments, unique to individual patients and complex to manufacture. We see tremendous potential for the cell and gene therapy platform we are building within GSK, however the complexity of current manufacturing processes limits their use to local treatment of small patient populations. Working with Miltenyi Biotec, our vision is to transform current technology so that we can expand the possibilities for cell and gene therapy treatment to wider patient populations with broader geographical reach.”

Stefan Miltenyi, CEO of Miltenyi Biotec, said, “For more than 20 years we have been developing and providing cell therapy solutions to patients worldwide. Working together with the global experts at GlaxoSmithKline, we will accelerate innovation to broaden patient access to future personalized cell and gene therapy.”

Related Links:

GlaxoSmithKline
Miltenyi Biotec



New
Gold Member
Latex Test
SLE-Latex Test
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.